Cargando…

A Comprehensive Overview of Globally Approved JAK Inhibitors

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling through the JAK-STAT pathway, which regulates the transcription of several genes involved in inflammatory, immune, and canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shawky, Ahmed M., Almalki, Faisal A., Abdalla, Ashraf N., Abdelazeem, Ahmed H., Gouda, Ahmed M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146299/ https://www.ncbi.nlm.nih.gov/pubmed/35631587 http://dx.doi.org/10.3390/pharmaceutics14051001

Ejemplares similares

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
por: Almalki, Faisal A., et al.
Publicado: (2021)

In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases
por: Almalki, Faisal A., et al.
Publicado: (2021)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
por: Abourehab, Mohammed A. S., et al.
Publicado: (2021)

Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities
por: Shawky, Ahmed M., et al.
Publicado: (2020)

Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents
por: Shawky, Ahmed M., et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Some Novel Pyrrolizine Derivatives as COX Inhibitors with Anti-Inflammatory/Analgesic Activities and Low Ulcerogenic Liability
por: Gouda, Ahmed M., et al.
Publicado: (2016)

Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies
por: Abourehab, Mohammed A. S., et al.
Publicado: (2021)

A Comprehensive Overview of the Developments of Cdc25 Phosphatase Inhibitors
por: Abdelwahab, Ahmed Bakr, et al.
Publicado: (2022)

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects
por: Shi, Zhenfeng, et al.
Publicado: (2023)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Radi, Giulia, et al.
Publicado: (2021)

An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
por: Almalki, Faisal A.
Publicado: (2023)

A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
por: Dillon, Kerry-Ann L
Publicado: (2021)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
por: Ashour, Nada A, et al.
Publicado: (2022)

Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview
por: Mostafa, Ahmed, et al.
Publicado: (2018)

Gallibacterium anatis infection in poultry: a comprehensive review
por: Abd El-Ghany, Wafaa A., et al.
Publicado: (2023)

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)

JAK inhibitors and COVID-19
por: Levy, Gabriel, et al.
Publicado: (2022)

Molecular Bases of Serotonin Reuptake Inhibitor Antidepressant-Attributed Effects in COVID-19: A New Insight on the Role of Bradykinins
por: Gouda, Ahmed S., et al.
Publicado: (2022)

A comprehensive overview of eco-friendly bio-fertilizers extracted from living organisms
por: Ammar, Esraa E., et al.
Publicado: (2023)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

The global landscape of approved antibody therapies
por: Lyu, Xiaochen, et al.
Publicado: (2022)

A comprehensive insight into the role of zinc deficiency in the renin-angiotensin and kinin-kallikrein system dysfunctions in COVID-19 patients
por: Gouda, Ahmed S., et al.
Publicado: (2021)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
por: Imran, Mohd., et al.
Publicado: (2021)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
por: Minniti, C., et al.
Publicado: (2023)

Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2018)

Monkeypox Virus: A Comprehensive Overview of Viral Pathology, Immune Response, and Antiviral Strategies
por: Malik, Shiza, et al.
Publicado: (2023)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview
por: Ashraf-Uz-Zaman, Md, et al.
Publicado: (2020)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
por: Al-Karmalawy, Ahmed A., et al.
Publicado: (2021)

JAK-STAT pathway inhibitors in dermatology()
por: Miot, Hélio Amante, et al.
Publicado: (2023)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nikr72tlhvg9nnkk7qo5lqpcsk